drugset / Trial / NCT00753623

Clinical Management of Neuropathic Pain With Ramelteon

NCT00753623 ↗

RandomizedCrossoverTriple-blindTreatment

Summary

This proposal is to conduct a double-blinded, randomized, placebo-controlled, crossover clinical study to examine the hypothesis that ramelteon would reduce pain score and improve functional status in subjects with neuropathic pain.

Timeline

Start
2008-09
Primary completion
2010-12
Completion
2011-12

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment did not accrue as expected.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramelteon Unknown 8 mg —

Indications